Ratio of the ON orientation of the PSA promoter of B. fragilis, measured by qPCR, after ex vivo exposure to fecal filtrates of IBD patients before and after treatment with anti-TNF (4 patients on infliximab [HR] and 7 patients on Humira [HuR]). Data represent the median (line in box), IQR (box), and minimum/maximum (whiskers) (one-sided Wilcoxon rank-sum test,*p < 0.05.) Green: B. fragilis grown in a 1:1 ratio of M9 and PBS not exposed to fecal filtrates; orange: B. fragilis exposed to fecal filtrates of patients before anti-TNF treatment; yellow: B. fragilis exposed to fecal filtrates of patients after anti-TNF treatment. Each dot represents 3 individual experiments; lines connect experiments from the same patient; shapes are determined by the patients' treatments: circle, HR; triangle, HuR.
